Initial, long-term, and durable responses to terazosin, placebo, or other therapies for chronic prostatitis/chronic pelvic pain syndrome.
OBJECTIVES: To evaluate the initial, long-term, and durable response rates to terazosin, placebo, or other therapies in patients with chronic prostatitis/chronic pelvic pain syndrome. METHODS: A total of 100 subjects, aged 20 to 50 years, who met the National Institutes of Health criteria for chron...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
2004
|
| _version_ | 1797073253426003968 |
|---|---|
| author | Cheah, P Liong, M Yuen, K Teh, C Khor, T Yang, JR Yap, H Krieger, J |
| author_facet | Cheah, P Liong, M Yuen, K Teh, C Khor, T Yang, JR Yap, H Krieger, J |
| author_sort | Cheah, P |
| collection | OXFORD |
| description | OBJECTIVES: To evaluate the initial, long-term, and durable response rates to terazosin, placebo, or other therapies in patients with chronic prostatitis/chronic pelvic pain syndrome. METHODS: A total of 100 subjects, aged 20 to 50 years, who met the National Institutes of Health criteria for chronic prostatitis/chronic pelvic pain syndrome and had not previously been treated with alpha-blockers, were entered in a 14-week, double-blind comparison of terazosin or placebo therapy. Nonresponders and responders with subsequent relapse were treated with terazosin or other medications (open label). The criterion for response was a score of 0 to 2 on the National Institutes of Health Chronic Prostatitis Symptom Index quality-of-life item. The initial response was evaluated at week 14, and the long-term response was evaluated after a median of 38 weeks (range 34 to 42), regardless of any additional treatment. A durable response was defined as an initial response without additional treatment. RESULTS: Of the 43 patients in the terazosin group, 24 (56%) had an initial response compared with 14 (33%) of 43 subjects in the placebo group (P = 0.03). Long-term responses were noted in 23 (56%) of 41 assessable subjects treated with terazosin initially compared with 12 (32%) of 38 assessable subjects treated with placebo (P = 0.03). Of the nonresponders and initial responders with relapse, 7 (41%) of 17 subjects responded to terazosin compared with 7 (21%) of 34 given other treatment (P = 0.12). Durable responses occurred in 18 (44%) of the 41 assessable patients treated initially with terazosin and in 6 (16%) of 38 treated initially with placebo (P = 0.01). CONCLUSIONS: Patients treated with terazosin were more likely to have initial, long-term, and durable responses than those treated with placebo. |
| first_indexed | 2024-03-06T23:19:28Z |
| format | Journal article |
| id | oxford-uuid:683f6f57-c55a-45f2-9a0d-6bd0b2c064ba |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T23:19:28Z |
| publishDate | 2004 |
| record_format | dspace |
| spelling | oxford-uuid:683f6f57-c55a-45f2-9a0d-6bd0b2c064ba2022-03-26T18:43:39ZInitial, long-term, and durable responses to terazosin, placebo, or other therapies for chronic prostatitis/chronic pelvic pain syndrome.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:683f6f57-c55a-45f2-9a0d-6bd0b2c064baEnglishSymplectic Elements at Oxford2004Cheah, PLiong, MYuen, KTeh, CKhor, TYang, JRYap, HKrieger, J OBJECTIVES: To evaluate the initial, long-term, and durable response rates to terazosin, placebo, or other therapies in patients with chronic prostatitis/chronic pelvic pain syndrome. METHODS: A total of 100 subjects, aged 20 to 50 years, who met the National Institutes of Health criteria for chronic prostatitis/chronic pelvic pain syndrome and had not previously been treated with alpha-blockers, were entered in a 14-week, double-blind comparison of terazosin or placebo therapy. Nonresponders and responders with subsequent relapse were treated with terazosin or other medications (open label). The criterion for response was a score of 0 to 2 on the National Institutes of Health Chronic Prostatitis Symptom Index quality-of-life item. The initial response was evaluated at week 14, and the long-term response was evaluated after a median of 38 weeks (range 34 to 42), regardless of any additional treatment. A durable response was defined as an initial response without additional treatment. RESULTS: Of the 43 patients in the terazosin group, 24 (56%) had an initial response compared with 14 (33%) of 43 subjects in the placebo group (P = 0.03). Long-term responses were noted in 23 (56%) of 41 assessable subjects treated with terazosin initially compared with 12 (32%) of 38 assessable subjects treated with placebo (P = 0.03). Of the nonresponders and initial responders with relapse, 7 (41%) of 17 subjects responded to terazosin compared with 7 (21%) of 34 given other treatment (P = 0.12). Durable responses occurred in 18 (44%) of the 41 assessable patients treated initially with terazosin and in 6 (16%) of 38 treated initially with placebo (P = 0.01). CONCLUSIONS: Patients treated with terazosin were more likely to have initial, long-term, and durable responses than those treated with placebo. |
| spellingShingle | Cheah, P Liong, M Yuen, K Teh, C Khor, T Yang, JR Yap, H Krieger, J Initial, long-term, and durable responses to terazosin, placebo, or other therapies for chronic prostatitis/chronic pelvic pain syndrome. |
| title | Initial, long-term, and durable responses to terazosin, placebo, or other therapies for chronic prostatitis/chronic pelvic pain syndrome. |
| title_full | Initial, long-term, and durable responses to terazosin, placebo, or other therapies for chronic prostatitis/chronic pelvic pain syndrome. |
| title_fullStr | Initial, long-term, and durable responses to terazosin, placebo, or other therapies for chronic prostatitis/chronic pelvic pain syndrome. |
| title_full_unstemmed | Initial, long-term, and durable responses to terazosin, placebo, or other therapies for chronic prostatitis/chronic pelvic pain syndrome. |
| title_short | Initial, long-term, and durable responses to terazosin, placebo, or other therapies for chronic prostatitis/chronic pelvic pain syndrome. |
| title_sort | initial long term and durable responses to terazosin placebo or other therapies for chronic prostatitis chronic pelvic pain syndrome |
| work_keys_str_mv | AT cheahp initiallongtermanddurableresponsestoterazosinplaceboorothertherapiesforchronicprostatitischronicpelvicpainsyndrome AT liongm initiallongtermanddurableresponsestoterazosinplaceboorothertherapiesforchronicprostatitischronicpelvicpainsyndrome AT yuenk initiallongtermanddurableresponsestoterazosinplaceboorothertherapiesforchronicprostatitischronicpelvicpainsyndrome AT tehc initiallongtermanddurableresponsestoterazosinplaceboorothertherapiesforchronicprostatitischronicpelvicpainsyndrome AT khort initiallongtermanddurableresponsestoterazosinplaceboorothertherapiesforchronicprostatitischronicpelvicpainsyndrome AT yangjr initiallongtermanddurableresponsestoterazosinplaceboorothertherapiesforchronicprostatitischronicpelvicpainsyndrome AT yaph initiallongtermanddurableresponsestoterazosinplaceboorothertherapiesforchronicprostatitischronicpelvicpainsyndrome AT kriegerj initiallongtermanddurableresponsestoterazosinplaceboorothertherapiesforchronicprostatitischronicpelvicpainsyndrome |